These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38545425)

  • 1. Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched study.
    Magnoni F; Corso G; Maisonneuve P; Bianchi B; Accardo G; Sangalli C; Massari G; Rotili A; Nicosia L; Pesapane F; Montagna E; Mazzarol G; Galimberti V; Veronesi P; Curigliano G
    EClinicalMedicine; 2024 May; 71():102552. PubMed ID: 38545425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
    Martin M; Hegg R; Kim SB; Schenker M; Grecea D; Garcia-Saenz JA; Papazisis K; Ouyang Q; Lacko A; Oksuzoglu B; Reeves J; Okera M; Testa L; Shimizu C; Denduluri N; Adamchuk H; Dakhil S; Wei R; Forrester T; Fernandez MM; Zimmermann A; Headley D; Johnston SRD
    JAMA Oncol; 2022 Aug; 8(8):1190-1194. PubMed ID: 35653145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J;
    Ann Oncol; 2021 Dec; 32(12):1571-1581. PubMed ID: 34656740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
    Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
    Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 taiwan cancer registry index cases.
    Chen BF; Tsai YF; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Tseng LM; Huang CC
    Breast Cancer Res Treat; 2023 Oct; 201(3):547-560. PubMed ID: 37470893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
    Johnston SRD; Toi M; O'Shaughnessy J; Rastogi P; Campone M; Neven P; Huang CS; Huober J; Jaliffe GG; Cicin I; Tolaney SM; Goetz MP; Rugo HS; Senkus E; Testa L; Del Mastro L; Shimizu C; Wei R; Shahir A; Munoz M; San Antonio B; André V; Harbeck N; Martin M;
    Lancet Oncol; 2023 Jan; 24(1):77-90. PubMed ID: 36493792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
    Paluch-Shimon S; Neven P; Huober J; Cicin I; Goetz MP; Shimizu C; Huang CS; Lueck HJ; Beith J; Tokunaga E; Contreras JR; de Sant'Ana RO; Wei R; Shahir A; Nabinger SC; Forrester T; Johnston SRD; Harbeck N
    Ther Adv Med Oncol; 2023; 15():17588359231151840. PubMed ID: 36756142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
    J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive Lobular Carcinoma Has Worse Outcome Compared with Invasive Ductal Carcinoma in Stage IV Breast Cancer with Bone-Only Metastasis.
    Luo Y; Ma A; Huang S; Yu Y
    Breast Care (Basel); 2022 Jun; 17(3):296-305. PubMed ID: 35949419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary lymph node status and invasive lobular breast cancer : Analysis of the Clinical Tumor Register of the AGO Austria.
    Danzinger S; Pöckl K; Kronawetter G; Pfeifer C; Behrendt S; Gscheidlinger P; Harrasser L; Mühlböck H; Dirschlmayer W; Schauer C; Reitsamer R; Uher H; Schönau K; Delmarko I; Singer CF
    Wien Klin Wochenschr; 2023 Sep; 135(17-18):463-471. PubMed ID: 37010596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
    Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
    BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.
    Pramod N; Nigam A; Basree M; Mawalkar R; Mehra S; Shinde N; Tozbikian G; Williams N; Majumder S; Ramaswamy B
    Oncologist; 2021 Jun; 26(6):e943-e953. PubMed ID: 33641217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival.
    García-Fernández A; Lain JM; Chabrera C; García Font M; Fraile M; Barco I; Torras M; Reñe A; González S; González C; Piqueras M; Veloso E; Cirera L; Pessarrodona A; Giménez N
    Breast J; 2015; 21(5):533-7. PubMed ID: 26190560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lobular-Like Features and Outcomes of Mixed Invasive Ductolobular Breast Cancer (MIDLC): Insights from 54,403 Stage I-III MIDLC Patients.
    Lohani KR; Hoskin TL; Day CN; Yasir S; Boughey JC; Degnim AC
    Ann Surg Oncol; 2024 Feb; 31(2):936-946. PubMed ID: 37872454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
    Rothschild HT; Clelland EN; Abel MK; Chien AJ; Shui AM; Esserman L; Khan SA; Mukhtar RA
    Breast Cancer Res Treat; 2024 Jan; 203(2):245-256. PubMed ID: 37833450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
    Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
    Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer.
    Oesterreich S; Nasrazadani A; Zou J; Carleton N; Onger T; Wright MD; Li Y; Demanelis K; Ramaswamy B; Tseng G; Lee AV; Williams N; Kruse M
    J Natl Cancer Inst; 2022 Nov; 114(11):1511-1522. PubMed ID: 36239760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.